Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | CFB | P00751 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149814 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2PDE4BMAPTCRHBPCRHR2 | |
| SCHEMBL27589075 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2PDE4BMAPTCRHBPCRHR2 | |
| SCHEMBL27589074 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2PDE4BMAPTCRHBPCRHR2 | |
| SCHEMBL31327667 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2PDE4BMAPTCRHBPCRHR2 | |
| SCHEMBL4968813 | 0.86 | RIPK1 (0.47) | SMN1; SMN2MAPTCFBRIPK1ALDH1A1 | |
| SCHEMBL4968809 | 0.86 | RIPK1 (0.47) | SMN1; SMN2MAPTCFBRIPK1ALDH1A1 | |
| SCHEMBL27389358 | 0.84 | RIPK1 (0.43) | MAPTHTTRIPK1ALDH1A1 | |
| SCHEMBL25168074 | 0.84 | MAPT (0.48) | SMN1; SMN2PDE4BMAPTCRHBPCRHR2 | |
| SCHEMBL23703573 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2PDE4BMAPTCRHBPCRHR2 | |
| SCHEMBL25172254 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2PDE4BMAPTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | SMN1; SMN2 4151/4885PDE4B 896/4885MAPT 3229/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | SMN1; SMN2 4245/4885PDE4B 689/4885MAPT 3296/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | SMN1; SMN2 4213/4885PDE4B 969/4885MAPT 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.